Clinical Trial Update: A Multicentre, Open Label, Phase 1 Trial in Japan of the Mitogen Activated Protein Extracellular Signal Regulated Kinase (MEK) Inhibitor Pimasertib Given Orally to Subjects With Solid Tumors as Monotherapy [Phase 1]

View source ↗

Summary

A multicenter, open-label Phase 1 study in Japan evaluated the MEK inhibitor pimasertib in patients with advanced solid tumors; the trial was terminated with re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Pimasertib (pimasertib)

Snippet

Sponsor: Merck KGaA, Darmstadt, Germany | Conditions: Advanced Solid Tumors, Hepatocellular Carcinoma | Phase 1 | Status: TERMINATED | Results posted: 2017-03-29